Literature DB >> 20102698

Sites in the AAV5 capsid tolerant to deletions and tandem duplications.

Kaoru Hida1, Sang Y Won, Giovanni Di Pasquale, Justin Hanes, John A Chiorini, Marc Ostermeier.   

Abstract

Gene therapy vectors based on adeno-associated virus (AAV) have shown much promise in clinical trials for the treatment of a variety of diseases. However, the ability to manipulate and engineer the viral surface for enhanced efficiency is necessary to overcome such barriers as pre-existing immunity and transduction of non-target cells that currently limit AAV applications. Although single amino acid changes and peptide insertions at select sites have been explored previously, the tolerance of AAV to small deletions and tandem duplications of sequence has not been globally addressed. Here, we have generated a large, diverse library of >10(5) members containing deletions and tandem duplications throughout the viral capsid of AAV5. Four unique mutants were identified that maintain the ability to form viral particles, with one showing improved transduction on both 293T and BEAS-2B cells. This approach may find potential use for the generation of novel variants with improved and altered properties or in the identification of sites that are tolerant to insertions of targeting ligands. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102698      PMCID: PMC2840209          DOI: 10.1016/j.abb.2010.01.009

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  36 in total

1.  Insertional mutagenesis of AAV2 capsid and the production of recombinant virus.

Authors:  J E Rabinowitz; W Xiao; R J Samulski
Journal:  Virology       Date:  1999-12-20       Impact factor: 3.616

2.  Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain.

Authors:  J B Nguyen; R Sanchez-Pernaute; J Cunningham; K S Bankiewicz
Journal:  Neuroreport       Date:  2001-07-03       Impact factor: 1.837

3.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

4.  Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.

Authors:  Glenn P Niemeyer; Roland W Herzog; Jane Mount; Valder R Arruda; D Michael Tillson; John Hathcock; Frederik W van Ginkel; Katherine A High; Clinton D Lothrop
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

5.  Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes.

Authors:  C L Halbert; E A Rutledge; J M Allen; D W Russell; A D Miller
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.

Authors:  P Wu; W Xiao; T Conlon; J Hughes; M Agbandje-McKenna; T Ferkol; T Flotte; N Muzyczka
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.

Authors:  W Shi; G S Arnold; J S Bartlett
Journal:  Hum Gene Ther       Date:  2001-09-20       Impact factor: 5.695

8.  Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.

Authors:  C E Wobus; B Hügle-Dörr; A Girod; G Petersen; M Hallek; J A Kleinschmidt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer.

Authors:  J Zabner; M Seiler; R Walters; R M Kotin; W Fulgeras; B L Davidson; J A Chiorini
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 10.  Gene therapy using adeno-associated virus vectors.

Authors:  Shyam Daya; Kenneth I Berns
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

View more
  9 in total

1.  Structural insights into adeno-associated virus serotype 5.

Authors:  Lakshmanan Govindasamy; Michael A DiMattia; Brittney L Gurda; Sujata Halder; Robert McKenna; John A Chiorini; Nicholas Muzyczka; Sergei Zolotukhin; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

2.  Extensive libraries of gene truncation variants generated by in vitro transposition.

Authors:  Aleardo Morelli; Yari Cabezas; Lauren J Mills; Burckhard Seelig
Journal:  Nucleic Acids Res       Date:  2017-06-02       Impact factor: 16.971

3.  AAV's anatomy: roadmap for optimizing vectors for translational success.

Authors:  Angela M Mitchell; Sarah C Nicolson; Jayme K Warischalk; R Jude Samulski
Journal:  Curr Gene Ther       Date:  2010-10       Impact factor: 4.391

Review 4.  Synthetic virology: engineering viruses for gene delivery.

Authors:  Caitlin M Guenther; Brianna E Kuypers; Michael T Lam; Tawana M Robinson; Julia Zhao; Junghae Suh
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-09-04

5.  Random Insertion of mCherry Into VP3 Domain of Adeno-associated Virus Yields Fluorescent Capsids With no Loss of Infectivity.

Authors:  Justin Judd; Fang Wei; Peter Q Nguyen; Lawrence J Tartaglia; Mavis Agbandje-McKenna; Jonathan J Silberg; Junghae Suh
Journal:  Mol Ther Nucleic Acids       Date:  2012-11-13       Impact factor: 10.183

6.  A transposase strategy for creating libraries of circularly permuted proteins.

Authors:  Manan M Mehta; Shirley Liu; Jonathan J Silberg
Journal:  Nucleic Acids Res       Date:  2012-02-07       Impact factor: 16.971

7.  Directed evolution of adeno-associated virus 5 capsid enables specific liver tropism.

Authors:  Yuqiu Wang; Chen Yang; Hanyang Hu; Chen Chen; Mengdi Yan; Feixiang Ling; Kathy Cheng Wang; Xintao Wang; Zhe Deng; Xinyue Zhou; Feixu Zhang; Sen Lin; Zengmin Du; Kai Zhao; Xiao Xiao
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-21       Impact factor: 10.183

8.  Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy.

Authors:  Dwaipayan Sen; Balaji Balakrishnan; Nishanth Gabriel; Prachi Agrawal; Vaani Roshini; Rekha Samuel; Alok Srivastava; Giridhara R Jayandharan
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

9.  Accessing unexplored regions of sequence space in directed enzyme evolution via insertion/deletion mutagenesis.

Authors:  Stephane Emond; Maya Petek; Emily J Kay; Brennen Heames; Sean R A Devenish; Nobuhiko Tokuriki; Florian Hollfelder
Journal:  Nat Commun       Date:  2020-07-10       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.